BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment